RECENT DISCLOSURES OF CLINICAL CANDIDATES HIGHLIGHTS FROM THE SOCIETY OF MEDICINES RESEARCH SYMPOSIUM, HELD DECEMBER 4, 2014-NATIONAL HEART & LUNG INSTITUTE, LONDON, UK

被引：7

作者：

Collingwood, S. P.

Ratcliffe, A. J.

Pryde, D.

Porter, R.

机构：

来源：

DRUGS OF THE FUTURE | 2015年 / 40卷 / 01期

关键词：

Ibrutinib; GSK-2245035; CGM-097; Ridinilazole; KINASE INHIBITOR IBRUTINIB; DESIGN; DISCOVERY; SCN9A; SITE;

D O I：

10.1358/dof.2015.040.01.2273384

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This symposium featured an international line-up of speakers presenting on the discovery and clinical development of novel therapeutic agents. The program included the Society of Medicines Research (SMR) Award Lecture, given by Dr. Betty Chang from Pharmacyclics on the discovery and development of the marketed drug ibrutinib, as well as talks, several representing first U.K. disclosures, on Toll-like receptor 7 (TLR7) agonists, Na(v)1.7 modulators, inhibitors of Clostridium difficile, Mdm2 inhibitors, muscarinic M 1 receptor agonists and beta-secretase 1 (BACE1) inhibitors. The meeting was held at the National Heart and Lung institute, Kensington, London, U.K. and was organized by the authors of this report.

引用

页码：81 / 91

页数：11

共 22 条

[1] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[2]

Brown G. A., Patent No. [WO 2014045031, 2014045031]

[3]

Brown G. A., Patent No. [WO 2013072705, 2013072705]

[4] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[5]

Chang B. Y., 2013, 49 ANN M AM SOC CLIN

[6] Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients [J].

Chang, Betty Y. ;

Francesco, Michelle ;

De Rooij, Martin F. M. ;

Magadala, Padmaja ;

Steggerda, Susanne M. ;

Huang, Min Mei ;

Kuil, Annemieke ;

Herman, Sarah E. M. ;

Chang, Stella ;

Pals, Steven T. ;

Wilson, Wyndham ;

Wiestner, Adrian ;

Spaargaren, Marcel ;

Buggy, Joseph J. ;

Elias, Laurence .

BLOOD, 2013, 122 (14) :2412-2424

[7] An SCN9A channelopathy causes congenital inability to experience pain [J].

Cox, James J. ;

Reimann, Frank ;

Nicholas, Adeline K. ;

Thornton, Gemma ;

Roberts, Emma ;

Springell, Kelly ;

Karbani, Gulshan ;

Jafri, Hussain ;

Mannan, Jovaria ;

Raashid, Yasmin ;

Al-Gazali, Lihadh ;

Hamamy, Henan ;

Valente, Enza Maria ;

Gorman, Shaun ;

Williams, Richard ;

McHale, Duncan P. ;

Wood, John N. ;

Gribble, Fiona M. ;

Woods, C. Geoffrey .

NATURE, 2006, 444 (7121) :894-898

[8] Piperazine sulfonamide BACE1 inhibitors: Design, synthesis, and in vivo characterization [J].

Cumming, Jared ;

Babu, Suresh ;

Huang, Ying ;

Carrol, Carolyn ;

Chen, Xia ;

Favreau, Leonard ;

Greenlee, William ;

Guo, Tao ;

Kennedy, Matthew ;

Kuvelkar, Reshma ;

Le, Thuy ;

Li, Guoqing ;

McHugh, Nansie ;

Orth, Peter ;

Ozgur, Lynne ;

Parker, Eric ;

Saionz, Kurt ;

Stamford, Andrew ;

Strickland, Corey ;

Tadesse, Dawit ;

Voigt, Johannes ;

Zhang, Lili ;

Zhang, Qi .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (09) :2837-2842

[9]

Furet P., Patent No. [WO 2012176123, 2012176123]

[10] Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53 [J].

García-Echeverría, C ;

Chène, P ;

Blommers, MJJ ;

Furet, P .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (17) :3205-3208

← 1 2 3 →